ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, April 02, 2020 (GLOBE NEWSWIRE) — ArTara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 51,650 shares of common stock to four new employees.
Each stock option has an exercise price per share equal to $24.25 per share, ArTara’s closing trading price on April 1, 2020, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting date and 1/48th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee’s continued service relationship with ArTara through the applicable vesting dates.The Compensation Committee of ArTara’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).About ArTara TherapeuticsArTara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. ArTara’s current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company’s lead program, TARA-002, is being developed for the treatment of lymphatic malformations. ArTara’s second program, IV choline chloride, is a phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease.Company Contact:Blaine Davis
ArTara Therapeutics
Blaine.Davis@artaratx.com
646-844-0337Media Contact:Karen O’Shea, Ph.D.
LifeSci Communications
koshea@lifescicomms.com
929-469-3860
Each stock option has an exercise price per share equal to $24.25 per share, ArTara’s closing trading price on April 1, 2020, the grant date, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting date and 1/48th of the underlying shares vesting monthly thereafter over 36 months subject to the new employee’s continued service relationship with ArTara through the applicable vesting dates.The Compensation Committee of ArTara’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with NASDAQ Listing Rule 5635(c)(4).About ArTara TherapeuticsArTara is focused on identifying and optimizing product candidates for patients suffering from rare and specialty diseases where there is a significant unmet need. ArTara’s current development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. The Company’s lead program, TARA-002, is being developed for the treatment of lymphatic malformations. ArTara’s second program, IV choline chloride, is a phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease.Company Contact:Blaine Davis
ArTara Therapeutics
Blaine.Davis@artaratx.com
646-844-0337Media Contact:Karen O’Shea, Ph.D.
LifeSci Communications
koshea@lifescicomms.com
929-469-3860